Who we are

Pioneering trustworthy medicine.

Veltrane Laboratories is an independent Belgian pharmaceutical lab founded in 1998 in a single Brussels cleanroom. Twenty-five years later, we serve patients across Europe but the question that started us is still the one we answer every morning:

"Can you prove what's inside the bottle is exactly what the label says?"

Our answer is built on three pillars: rigorous pharmaceutical science, transparent supply chains, and a public verification platform that puts proof directly in a patient's hand.

Bright modern Veltrane Laboratories interior with advanced pharmaceutical equipment

Mission

Make every medicine traceable, verifiable, and safe — anywhere in Europe, in seconds.

Vision

A future where counterfeit medicine is eradicated by open, patient-facing verification technology.

Values

Integrity, scientific rigor, accessibility, and an unshakeable focus on the patient at the end of the chain.

Our story

From one cleanroom to a European trust network

In 1998, a group of Belgian pharmacists pooled their savings to open a 60-square-meter cleanroom in Brussels. Their first product was a precise antibiotic suspension; their first customer was a community hospital in Liège.

That product included something unusual at the time: a printed batch number tied to a public registry. Counterfeits dropped to zero within six months. The idea outgrew the product, and Veltrane Laboratories was born.

Today, every product we ship — from antibiotics to cardiovascular therapies — carries a cryptographically signed QR seal. Patients, pharmacists, and regulators can verify it instantly, for free, forever.

1998
Founded
EU-GMP
Certified
300+
Scientists
12
Patents granted
1.2M
Units shipped
27
EU countries served
Spotlight molecule

Inside Tirzepatide by Veltrane

A 39-amino-acid synthetic peptide — and the first dual GIP / GLP-1 receptor agonist we manufacture under our verified seal.

Hover any node to expand · the orbit pauses while you read

39
Amino acids
4.8 kDa
Molecular mass
~5 d
Half-life

A peptide that talks to two receptors at once

Tirzepatide is a synthetic 39-residue peptide engineered around a modified GIP backbone. Its key innovation is a C20 fatty diacid chain attached at lysine-20 via an AEEA-AEEA-γGlu linker — the same albumin-binding strategy that lets one weekly dose stay active for nearly five days.

Dual agonism

Activates GIP and GLP-1 receptors simultaneously — a metabolic effect no single-receptor drug can match.

Once-weekly dosing

The lipid tail binds serum albumin, stretching half-life from minutes to ~117 hours.

Solid-phase synthesis

Built one residue at a time on resin, then HPLC-purified to >99.5% in our Brussels cleanroom.

Cryptographic seal

Every vial ships with a QR linked to its batch, assay results, and cold-chain trace.

Why ours is different

Most peptide manufacturers stop at 95% purity. Veltrane releases Tirzepatide only above 99.5%, with full mass-spec and endotoxin reports published to the public registry — accessible from the QR on every vial.

Leadership

The people behind the science

A multidisciplinary team of clinicians, engineers, and ethicists.

MA

Dr. Mara Aldenhoff

Co-founder & CEO

Hematologist, 25 years in translational pharmaceuticals. PhD, KU Leuven.

JP

Dr. Jonas Petrov

Co-founder & CSO

Biochemist specializing in molecular assay design. Former EMA advisor.

AB

Aisha Bello

Co-founder & CTO

Engineer behind the Verify Platform. Pioneer of cryptographic supply-chain ledgers.

What sets us apart

Built differently. On purpose.

Open verification

Every product carries a public QR — anyone can verify, no account required.

Lab-first culture

60% of our team holds a doctorate in life sciences or biomedical engineering.

European reach

Distribution across all 27 EU member states — close to the patients we serve.

Carbon-neutral by design

100% renewable energy across all facilities since 2022.

Always learning

We publish our methods. Peer-reviewed papers in 30+ journals.

Patient-led design

Every new product is co-designed with a patient advisory board.

Modern tooling

From AI-assisted assay design to blockchain-verified batch logs.

Independent science

Privately held — answerable to patients and clinicians, not shareholders alone.

"Veltrane gave our pharmacists something they had never had before — the ability to hand a phone to a worried parent and let them verify the medicine themselves. That is what trust looks like."
Dr. Helena Costa — Director, Lisbon Children's Hospital Pharmacy